Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed CFO
Quarterly results
CFO resigned
CC transcript
Appointed director
OSIRIS THERAPEUTICS, INC. (OSIR) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/29/2019 15-12B Form 15-12B - Securities registration termination [Section 12(b)]:
04/17/2019 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
04/17/2019 4 FRIEDLI PETER (Director) has filed a Form 4 on OSIRIS THERAPEUTICS, INC.
Txns: Disposed/sold 10,204,404 shares @ $19, valued at $193.9M
Disposed/sold 4,103,301 shares @ $19, valued at $78M
Disposed/sold 500,000 shares @ $19, valued at $9.5M
Disposed/sold 2,750 shares @ $19, valued at $52.3k
04/17/2019 4 Keefer Jason (Chief Commercial Officer) has filed a Form 4 on OSIRIS THERAPEUTICS, INC.
Txns: Disposed/sold 4,000 shares @ $19, valued at $76k
Disposed/sold 16,000 options to buy @ $6.8, valued at $108.8k
Disposed/sold 20,000 options to buy @ $10.53, valued at $210.6k
04/17/2019 4 Danilkovitch Alla (Chief Scientific Officer) has filed a Form 4 on OSIRIS THERAPEUTICS, INC.
Txns: Disposed/sold 9,375 shares @ $19, valued at $178.1k
Disposed/sold 8,000 options to buy @ $7.74, valued at $61.9k
Disposed/sold 5,000 options to buy @ $6.46, valued at $32.3k
Disposed/sold 9,000 options to buy @ $7.13, valued at $64.2k
Disposed/sold 6,000 options to buy @ $5.08, valued at $30.5k
Disposed/sold 10,000 options to buy @ $7.73, valued at $77.3k
Disposed/sold 1,436 options to buy @ $14, valued at $20.1k
Disposed/sold 18,564 options to buy @ $14, valued at $259.9k
Disposed/sold 7,644 options to buy @ $18.4, valued at $140.6k
Disposed/sold 17,356 options to buy @ $18.4, valued at $319.4k
Disposed/sold 24,997 options to buy @ $6.8, valued at $170k
04/17/2019 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
04/17/2019 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
04/17/2019 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
04/17/2019 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
04/17/2019 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
04/17/2019 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "Amended and Restated Articles of Incorporation of the Company",
"Amended and Restated Bylaws of the Company",
"Osiris Therapeutics, Inc. Announces Closing of Acquisition by Smith & Nephew plc"
04/17/2019 GN Osiris Therapeutics, Inc. Announces Closing of Acquisition by Smith & Nephew plc
04/17/2019 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
04/17/2019 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
04/16/2019 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
04/12/2019 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
04/10/2019 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
04/10/2019 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
03/27/2019 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
03/27/2019 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
03/20/2019 SC 14D9 Form SC 14D9 - Solicitation, recommendation statements:
03/20/2019 SC TO-T Form SC TO-T - Tender offer statement by Third Party:
03/15/2019 10-K Annual Report for the period ended December 31, 2018
03/14/2019 GN OSIRIS THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
03/12/2019 SC14D9C Form SC14D9C - Written communication relating to third party tender offer:
03/12/2019 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Agreement and Plan of Merger, by and among Smith & Nephew plc, Smith & Nephew Consolidated, Inc., Papyrus Acquisition Corp. and Osiris Therapeutics, Inc"
03/12/2019 SC TO-C Form SC TO-C - Written communication relating to an issuer or third party:
03/12/2019 SC14D9C Form SC14D9C - Written communication relating to third party tender offer:
03/12/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "[email protected]",
"Letter from Samson Tom, President and Chief Executive Officer of Osiris Therapeutics, Inc., to Employees of Osiris Therapeutics, Inc.",
"Frequently Asked Questions"
02/28/2019 GN Predictive Technology Group Names Jay M. Moyes to Its Board of Directors
11/29/2018 3 Tom Samson (President & CEO) has filed a Form 3 on OSIRIS THERAPEUTICS, INC.
11/26/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/26/2018 GN Osiris Therapeutics, Inc. Appoints Samson Tom, PhD, MBA to Serve as President and Chief Executive Officer
11/08/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Summary Notice of Pendency and Proposed Settlement of Shareholder Derivative Actions"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy